Effect of process indicators on the episode sensitivity of mammography Tytti Sarkeala, MSc Finnish Cancer Registry Ahti Anttila Matti Hakama Irma Saarenmaa.

Slides:



Advertisements
Similar presentations
Breast Screening Programme, England, Statistics for : Graphs
Advertisements

†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.
Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.
EUROCHIP Health Indicators for Monitoring Cancer in Europe Health Monitoring Program (HMP) EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
Somaiya Medical College and Maina Foundation Five Year Project for Raising breast Cancer Awareness in Pratikshanagar - Mumbai.
¡Celebremos La Salud!: A cancer prevention program for Hispanic and non-Hispanic White women living in a rural area Silvia Tejeda, MPH Doctoral Candidate.
Cervical cancer screening in Estonia: present situation Piret Veerus Department of Epidemiology and Biostatistics National Institute for Health Development.
Early Detection of breast cancer Anthony B. Miller, MD, FRCP Associate Director, Research, Dalla Lana School of Public Health, University of Toronto, Canada.
Breast Imaging Made Brief and Simple
HEAPHY 1 & 2 DIAGNOSTIC James HAYES Fri 30 th Aug 2013 Session 2 / Talk 4 11:33 – 12:00 ABSTRACT To estimate population attributable risks for modifiable.
Chronic diseases 1.Chronic diseases have long and variable preclinical phases. 2.The preclinical phase is that portion of the disease natural history during.
EUROCHIP - EUROpean Cancer Health Indicators Project A project supported by the European Commission Andrea Micheli 1, Paolo Baili 1, Carmen Martinez 2,
NHS Breast Screening Programme (NHSBSP) – Forrest report To detect early, non-palpable disease in WOMEN Mammogram Every 3 years 50 and over (47-73.
Breast Cancer screening in the NHS Dr D J Rohan Subasinghe.
Breast cancer – UK The statistics in this presentation are based on the Breast CancerStats report published in However, the incidence, mortality.
EUROCHIP-2 European Public Health Action on Cervical Cancer Screening GRELL Palma de Majorca Public Health Program EUROPEAN COMMISSION: HEALTH &
Breast Cancer Detection, Treatment, and Survival in Medicare and Medicaid Insured Patients Cathy J. Bradley, Ph.D. Professor of Health Administration Co-leader,
Knowledge, Cancer Fatalism and Spirituality as Predictors of Breast Cancer Screening Practices for African American and Caucasian Women Staci T. Anderson,
Breast cancer screening Mammography is the most widely used screening modality, with solid evidence of benefit for women aged 40 to 74 years Clinical breast.
Mammography Screening Information for Providers Indian Health Service National GPRA Team.
Bayesian Network for Predicting Invasive and In-situ Breast Cancer using Mammographic Findings Jagpreet Chhatwal1 O. Alagoz1, E.S. Burnside1, H. Nassif1,
Statistics in Screening/Diagnosis
HSB examples from Finland Nea Malila Mass Screening Registry, Cancer Society of Finland and University of Tampere, Tampere School of Public Health.
Extending the Gail model for Breast Cancer Risk Prediction to Account for Modifiable Factors in the Italian Population. Calza S, Ferraroni M, Decarli A.
NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONS EUROCHIP-2 THE ACTION Project & news EUROCHIP-2 THE ACTION Project & news Public.
Clare Rogers Consultant Breast Surgeon Doncaster and Bassetlaw Hospitals.
Cancer Incidence and Mortality in Massachusetts, Bureau of Health Statistics, Research and Evaluation Massachusetts Department of Public Health.
EPIB-591 Screening Jean-François Boivin 29 September
Kalavathy Mathur chennath 1, Meera Radhakrishnan 1 Assistant Professor Regional Cancer Centre Trivandrum Kerala, India.
Reliability of Screening Tests RELIABILITY: The extent to which the screening test will produce the same or very similar results each time it is administered.
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
“The African American Prostate Cancer Crisis in Numbers”
Alaska Native Tumor Registry Alaska Native Epidemiology Center 40-Year Trends in Cancer Incidence among Alaska Native People
Improvement in Screening Radiologists’ Performance in an Organized Screening Program Nancy A. T. Wadden, MD, FRCPC Gregory Doyle, BSc, MBA Breast Screening.
AIM Statement The use of reminders to eligible patients in the Resident Clinic to have a mammogram will improve rates of screening. Over a 6 month period,
Trends in Cervical & Breast Cancer Screening Practices among Women in Rural & Urban Areas of the United States AcademyHealth 2008 Gender and Health Interest.
Incorporating Multiple Evidence Sources for the Assessment of Breast Cancer Policies and Practices J. Jackson-Thompson, Gentry White, Missouri Cancer Registry,
BASELINE ASSESSMENT OF CHLAMYDIA REINFECTION IN REGION VIII FAMILY PLANNING CLINICS FOR Hamby, Y, JSI Research & Training Institute Donovan,
Breast Cancer Screening Guidelines Across Canada Environmental Scan July 2015.
The Inflammatory Breast Cancer Cancer Registry Paul H. Levine, M.D. Paul H. Levine, M.D. The George Washington University School of Public Health and Health.
Senior Statistician Per-Henrik Zahl, MA MD PhD
Door to Balloon Time: Does it Matter? Tale of Two Studies.
Date of download: 2/26/2013 Copyright © 2012 American Medical Association. All rights reserved. From: Incidence of Breast Cancer With Distant Involvement.
Breast Screening Programme Statistics for , England: Graphs.
BC Cancer Agency CARE & RESEARCH Breast Cancer Mortality After Screening Mammography in British Columbia Women Andrew J. Coldman, Ph.D. Norm Phillips,
Colorectal Cancer Screening Implementation of a public health programme An Expert Group on Colorectal Cancer Screening Cancer Society of Finland, Finnish.
Trends in Diabetes Incidence: The Framingham Heart Study Featured Article: Tobin M. Abraham, Karol M. Pencina, Michael J. Pencina, and Caroline S. Fox.
Appendix 2 Comparison of screening from age 20 and age 25 Table of harms and benefits.
Date of download: 5/31/2016 From: Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years: A Comparative Modeling.
Trends in Colorectal Cancer Incidence Rates by Race, Age and Indices of Access to Medical Care in the U.S., Yongping Hao, PhD 1 Ahmedin Jemal,
BREAST CANCER BY STAGE OF DISEASE AT DIAGNOSIS, CENTRAL OKLAHOMA Arthur Owora, MPH; Aaron Wendelboe, PhD; David Thompson, PhD; Janis Campbell, PhD The.
Cervical cancer among Asian subgroups in California, Janet Bates, MD MPH California Cancer Registry NAACCR Annual Meeting Denver, Colorado June.
Date of download: 6/29/2016 From: Overdiagnosis of Invasive Breast Cancer Due to Mammography Screening: Results From the Norwegian Screening Program Ann.
Arnold School of Public Health Health Services Policy and Management 1 Women’s Cancer Screening Services Utilization Versus Their Insurance Source Presenter:
Lower Mammography Use is Associated with the Geographic Clustering of Late-stage Breast Cancer in Saint Louis City Min Lian, Donna B. Jeffe, Mario Schootman.
Date of download: 7/6/2016 From: Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies: Model Estimates.
Breast Screening Programme
Breast Screening Programme, England, Statistics for : Graphs
The communication of benign biopsy results in breast cancer screening
Population-Based Breast Cancer Screening With Risk-Based and Universal Mammography Screening Compared With Clinical Breast Examination A Propensity Score.
Mammograms and Breast Exams: When to start /stop mammograms
Kathleen England Neville Calleja 20th October 2017
Presenter: Wen-Ching Lan
Access and utilisation of cervical cancer screening services among four African immigrant communities in Finland: A qualitative study MERH, May 2018,
Breast Cancer Screening Rates Highest in Sweden and the U.S.
ESTIMATING THE EFFICIENCY OF THREE NATIONAL CANCER SCREENING PROGRAMMES USING THE POPULATION-BASED CANCER REGISTRY DATA IN SLOVENIA Vesna ZADNIK MD,
Sickness absence as an indicator of health?
International Trends in Female Breast Cancer Incidence and Mortality Rates NAACCR/IACR 2019 MaryBeth Culp, MPH Presented by Lindsey Torre, MSPH.
Geographical and temporal differences in gastric and oesophageal cancer in Europe
How to interpret the geographical variations in the incidence of bladder tumours in Europe
Presentation transcript:

Effect of process indicators on the episode sensitivity of mammography Tytti Sarkeala, MSc Finnish Cancer Registry Ahti Anttila Matti Hakama Irma Saarenmaa

Background (Sarkeala et. al. 2004, 2005) screening coverage 100% (50-59), 25% (60-69) recall rate differences fourfold ( %) differences in screening sensitivity?

Screening sensitivity test – screening mammogram episode – screening mammogram and further assessments programme – non-attenders

Episode sensitivity in Finland, aim to examine the episode sensitivity using the interval cancer definitions recommended by the European Commission and the IARC to explore associations between the episode sensitivity and process indicators (recall rate) to assess relations between the episode sensitivity and mortality (on-going)

Episode sensitivity in Finland, definitions (Sarkeala et. al. 2006) episode sensitivity: – screen-detected breast cancers / (screen-detected + interval breast cancers) – 1 – (incidence of interval breast cancers / breast cancer incidence in the absence of screening) interval cancers: – breast cancers identified between two successive screens or within 27 (23) months since the previous screen among women, whose previous screening episode was negative

Episode sensitivity in Finland, material ten centres of the Cancer Society of Finland women aged study period screening visits – 2716 screen-detected breast cancers – 1390 interval breast cancers

Episode sensitivity in Finland, methods breast cancers confirmed and identified from the nationwide Finnish Cancer Registry linkage with a personal identifier background trend – incidences from by area – 2.7% annual increase in risk Poisson regression for statistical evaluation

Episode sensitivity in Finland, overall results (subsequent screens) by the detection method the episode sensitivity was 65% and by the incidence method 54% within the first follow-up year the episode sensitivity was 70%, within the second year 38% (incidence method) the episode sensitivity decreased towards the end of the study period

Episode sensitivity in Finland, discussion Finland Denmark The Netherlands Norway EU % (63-78)68%74%78%>70% % (35-41)39%45%36%>50%

Subsequent screens

Episode sensitivity in Finland, associations in the centre-specific analysis, the episode sensitivity increased 13% per one percent absolute increase in the recall rate (p=0.008)

Episode sensitivity in Finland, discussion Finland Denmark The Netherlands Norway EU % (63-78)68%74%78%>70% % (35-41)39%45%36%>50%

Episode sensitivity in Finland, discussion detection method is potentially biased due to lead time and overdiagnosis incidence method is sensitive to correct estimation of background incidence and to selection of screening attendants

Episode sensitivity in Finland, conclusions overall estimates are comparable with those from other European countries centre-specific variation is large and it is connected with variation in recall rates whether the variability in episode sensitivity reflects variability also in the effectiveness of mammography is yet unknown